ANTI-COMPLEMENT C1S ANTIBODIES AND USES THEREOF
2 Assignments
0 Petitions
Accused Products
Abstract
The present disclosure provides antibodies that bind complement C1s protein; and nucleic acid molecules that encode such antibodies. The present disclosure also provides compositions comprising such antibodies, and methods to produce and use such antibodies, nucleic acid molecules, and compositions.
2 Citations
96 Claims
-
1. -80. (canceled)
- 81. An antibody that inhibits a component of the classical complement pathway, wherein the inhibition of the component reduces cleavage of complement component C4, and wherein the antibody does not inhibit cleavage of complement component C2.
-
92. A method of inhibiting activation of C4 in an individual in need thereof, the method comprising administering to the individual a pharmaceutical composition comprising:
-
a) an anti-C1s antibody in an amount effective to maintain a serum concentration of the anti-C1s antibody of at least 25 μ
g/ml, wherein the anti-C1s antibody comprises light chain complementarity determining regions (CDRs) of an antibody light chain variable region comprising amino acid sequence SEQ ID NO;
7 and heavy chain CDRs of an antibody heavy chain variable region comprising amino acid sequence SEQ ID NO;
8; andb) a pharmaceutically acceptable excipient. - View Dependent Claims (93, 94, 95, 96)
-
Specification